| Company Name: | Panacos Pharmaceuticals, Incorporated | | Ticker Symbol: | PANC | | | WWW Address: | www.panacos.com | | CEO: | Dr. Alan W. Dunton, M.D. | | No. of Employees: | 41 | | Common Issue Type: | CS | | Business Description: | A development-stage biotechnology Company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat HIV and other major human viral diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.0231 |  -0.0009 | 0.022 | 0.0241 | 0.0241 | 0.04 | 0.03 | 57084 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1.9 | 53.6 | 1.84 | -0.70 | 0.00 | 0.0 | 0.0 | 0.81 - 0.01 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.04 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1.9 | mil |
| Latest Shares Outstanding | 53.6 | mil |
| Earnings pS (EPS) | -0.70 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 4,390 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 52.5 | mil |
| Float as % of Shares Outstanding | 97.8 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 11,125.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 23,542.40 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -120.2 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -217.7 | % |
| Current Ratio | 2.1 | |
| Leverage Ratio (Assets/Equity) | 5.6 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 3.45 | |
| LT Debt/Total Capital | 68.0 | % |
| Working Capital pS | 0.27 | $ |
| Cash pS | 0.40 | $ |
| Book-Value pS | 0.10 | $ |
| Tangible Book-Value pS | 0.10 | $ |
| Cash Flow pS | -0.64 | $ |
| Free Cash Flow pS | -0.58 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.35 | |
| Price/Tangible Book Ratio | 0.35 | |
| Price/Cash Flow | -0.1 | |
| Price/Free Cash Flow | -0.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 300.0 | 381 | 9,196 | 48,027 |
| 4 Weeks | 0.05 | 0.01 | 0.04 | 0.0 | 97 | 10,438 | 187,885 |
| 13 Weeks | 0.24 | 0.01 | 0.12 | -66.7 | 37 | 8,834 | 521,208 |
| 26 Weeks | 0.55 | 0.01 | 0.37 | -89.2 | 17 | 5,250 | 645,794 |
| 52 Weeks | 0.81 | 0.01 | 0.66 | -93.9 | 10 | 3,815 | 953,815 |
| YTD | 0.24 | 0.01 | - | -71.4 | 32 | 9,734 | 506,162 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.02 | 0.02 | 0.08 | 0.23 | 0.32 | 1.84 | 1.77 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -35.23 | 64.6 | -54.18 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -29.54 | NA | -27.11 |
| R&D | 8.34 | NA | 10.28 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -51.3 | -20.0 | -36.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.04 | 0.00 | 0.05 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 82.13 |
| Current Ratio | 7.2 |
| Quick Ratio (Acid Test) | 7.1 |
| Liquidity Ratio (Cash) | 7.07 |
| Receivables Turnover | 1.7 |
| Average Collection Period | 212 |
| Working Capital/Equity | 158.5 |
| Working Capital pS | 0.85 |
| Cash-Flow pS | -0.68 |
| Free Cash-Flow pS | -0.58 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.07 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 48.2 |
| Total Debt/Equity (Gearing Ratio) | 0.67 |
| LT Debt/Equity | 0.65 |
| LT Debt/Capital Invested | 40.8 |
| LT Debt/Total Liabilities | 70.4 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 2.33 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.05 |
| Tobin's Q Ratio | 0.03 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | 0.63 |
| Enterprise Value (EV)/Free Cash Flow | 1.60 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.35 |
| Price/Book Ratio - LTM | 0.35 |
| Price/Cash Flow Ratio | -0.1 |
| Price/Free Cash Flow Ratio - LTM | -0.1 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.35 |
| Current Liabilities pS | 0.14 |
| Tangible Book Value pS - LTM | 0.10 |
| Book Value pS - LTM | 0.10 |
| Capital Invested pS | 0.89 |
| Cash pS - LTM | 0.40 |
| Cash Flow pS - LTM | -0.64 |
| Free Cash Flow pS - LTM | -0.58 |
| Earnings pS (EPS) | -0.70 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -17,268.33 |
| Free Cash Flow Margin 5YEAR AVG | -6,744.03 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.01 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -78.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -84.8 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -67.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | -73.6 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 294 |
| Revenue per Employee | 4,390 |
| Net Income per Employee | -913,634 |
| Average Collection Period | 294 |
| Receivables Turnover | 1.7 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 1,852.78 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.07 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.17 |
| Revenue per $ Common Equity | 0.01 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 7133.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1255.7 |
| Research & Devlopment (R&D) as % of Revenue | 13938.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 13938.9 |
|
|  
|
| |
 |  |